Search

Your search keyword '"Mohs, Antje"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Mohs, Antje" Remove constraint Author: "Mohs, Antje"
49 results on '"Mohs, Antje"'

Search Results

1. Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment

2. Gut microbiota depletion exacerbates cholestatic liver injury via loss of FXR signalling

4. Intestinal Dysbiosis Amplifies Acetaminophen-Induced Acute Liver Injury

5. Functional role of CCL5/RANTES for HCC progression during chronic liver disease

7. Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis

10. Colitis protects from primary sclerosing cholangitis via bile acid synthesis suppression

11. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis

12. Nrf2 induces malignant transformation of hepatic progenitor cells by inducing β-catenin expression

14. MyD88-dependent signaling in non-parenchymal cells promotes liver carcinogenesis

16. NRF2/KEAP1 in hepatocytes controls fibro- and carcinogenesis in chronic liver disease

18. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis

21. FRI-334 - Cholestatic liver disease is alleviated by colitis-induced inhibition of bile acid synthesis

22. Disturbed gut microbiota and bile homeostasis in Giardia-infected mice contributes to metabolic dysregulation and growth impairment

24. Disturbed gut microbiota and bile homeostasis in Giardia -infected mice contributes to metabolic dysregulation and growth impairment

25. Gut microbiota drives hepatocarcinogenesis by promoting TLR4-dependent expansion of monocytic myeloid-derived suppressor cells

26. Gut microbiota maintains FXR activation and protects from fatal liver damage in a murine model of primary sclerosing cholangitis

30. PS-159-Intestinal dysbiosis fuels liver disease progression via NLRP3 in the Mdr2−/− mouse model of primary sclerosing cholangitis

33. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis

36. Intestinal Microbiota Protects against MCD Diet-Induced Steatohepatitis

37. Functional role of CCL5/RANTES for HCC progression during chronic liver disease

39. Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis.

40. Hepatic overexpression of cAMP-responsive element modulator α induces a regulatory T-cell response in a murine model of chronic liver disease

42. miR-155 targets Caspase-3 mRNA in activated macrophages

46. GS04 - Gut microbiota drives hepatocarcinogenesis by promoting TLR4-dependent expansion of monocytic myeloid-derived suppressor cells.

48. AS113 - Gut microbiota maintains FXR activation and protects from fatal liver damage in a murine model of primary sclerosing cholangitis.

49. Colitis ameliorates cholestatic liver disease via suppression of bile acid synthesis.

Catalog

Books, media, physical & digital resources